PD Therapeutics 2009: Poster Abstracts

The Michael J. Fox Foundation for Parkinson’s Research & The New York Academy of Sciences

Parkinson’s Disease Therapeutics Conference

New York, NY
September 30, 2009

 Poster Session on Novel Therapeutic Targets and Tools

 

Thomas G. Beach, MD, PhD, Sun Health Research Institute – “Brain & Body Donation Program of the Arizona Parkinson’s Disease Consortium” Abstract

Steven P. Braithwaite, PhD, Wyeth Pharmaceuticals – “Targeting LRRK2 for Drug Discovery” Abstract

Luke A. Esposito, PhD, ProteoTech Inc.  “New Small Molecule Inhibiting Agents of Alpha-Synuclein & Lewy Body Formation as Disease-Modifying Treatments for Parkinson's Disease”

Mark Frasier, PhD, The Michael J. Fox Foundation – “The Parkinson’s Progression Markers Initiative:  A Prospective Biomarkers Study” Abstract

David Grabli, MD, Hôpital de la Salpêtrière – “Development of a New Primate Model of Postural Disturbance by Lesioning Non Cholinergic Neurons of the Reticular Formation”

Ann M. Graybiel and Jill Crittenden, MIT – “Evaluation of the Striatum-Enriched Genes, CalDAG-GEF1 and CalDAG-GEF2, as Targets for the Treatment and Prevention of L-DOPA Induced Dyskinesias” Abstract

Chenjian Li, PhD, Weill Medical College of Cornell University – “BAC-Engineered Alpha-Synuclein Transgenic Rats” Abstract

Pamela J. McLean, PhD, Harvard University – “Hsp90 as a Target for Neuroprotective Agents in Parkinson's Disease” Abstract

Michael T. Rogan, PhD, The Michael J. Fox Foundation – “PD Online Research:  A Professional Collaborative Community for Rapid-Fire Problem Solving in Parkinson’s Disease Science” Abstract

 

 

Responses:
ABSTRACT: Brain and Body Donation Program of the Arizona Parkinson’s Disease Consortium
Thomas G Beach, Sun Health
16 Sep 2009 02:56 PM EST
Recognizing that increased knowledge of the clinicopathological correlates of Parkinson’s disease is critical to understanding the progression of the disease and developing novel treatment ... 
ABSTRACT: Hsp90 as a Target for Neuroprotective Agents in Parkinson’s Disease
Pamela J McLean, MGH
16 Sep 2009 03:10 PM EST
Cell death caused by alpha-synuclein is thought to play a central role in the pathogenesis of Parkinson’s disease. We have previously shown that a class of compounds called Hsp90 inhibitors can ... 
ABSTRACT: PD Online Research: A professional collaborative community for rapid-fire problem-solving in Parkinson’s disease science
Holli Kawadler, MJFF, et al.
16 Sep 2009 04:22 PM EST
PD Online Research (PDOR) is a collaborative community for technical discussion and problem-solving in Parkinson’s disease science, powered by he Michael J. Fox Foundation for ... 
ABSTRACT: BAC-Engineered Alpha-Synuclein Transgenic Rats
Chenjian Li, Cornell
17 Sep 2009 04:07 PM EST
A severe and unfortunate roadblock in Parkinson’s disease (PD) research is that to date no genetic mammalian models have recapitulated well the cardinal PD pathology of dopaminergic neuronal ... 
ABSTRACT: The Parkinson’s Progression Markers Initiative: A Prospective Biomarkers Study
Mark Frasier, MJFF
17 Sep 2009 04:09 PM EST
Parkinson’s disease (PD) interventional trials rely predominantly on clinical outcomes that often vary within subjects and are not consistent across subjects. Reliable and well-validated ... 
ABSTRACT: Evaluation of the Striatum-enriched Genes CalDAG-GEF1 and CalDAG-GEF2 as Targets for the Treatment and Prevention of L-DOPA Induced Dyskinesia
Ann Graybiel, MIT
17 Sep 2009 04:13 PM EST
The most widely prescribed therapy for Parkinson’s disease is levodopa (L-DOPA), which allows patients to regain motor control. However, many patients develop adverse reactions to L-DOPA, ... 
ABSTRACT: Targeting LRRK2 for Drug Discovery
Steven P Braithwaite, Wyeth
1 Oct 2009 10:19 AM EST
Mutations in Leucine Rich repeat Kinase 2 (LRRK2) lead to a form of autosomal dominant Parkinson’s Disease (PD) with symptoms and pathological hallmarks that are similar to sporadic forms of ...